{"id":"comirnaty-original-omicron-ba-4-5","safety":{"commonSideEffects":[{"rate":"40–50","effect":"Injection site pain"},{"rate":"30–40","effect":"Fatigue"},{"rate":"30–40","effect":"Headache"},{"rate":"20–30","effect":"Myalgia"},{"rate":"10–20","effect":"Fever"},{"rate":"10–20","effect":"Chills"}]},"_chembl":{"chemblId":"CHEMBL5791340","moleculeType":null,"molecularWeight":"319.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Comirnaty Original/Omicron BA.4-5 is a reformulated COVID-19 vaccine containing mRNA sequences encoding spike proteins from both the ancestral Wuhan strain and the Omicron BA.4-5 subvariants. The mRNA is delivered via lipid nanoparticles into host cells, where it is translated to produce spike antigen, triggering both humoral (antibody) and cellular (T-cell) immune responses. This bivalent approach aims to provide broader protection against multiple circulating SARS-CoV-2 variants.","oneSentence":"This bivalent mRNA vaccine encodes spike proteins from the original SARS-CoV-2 strain and the Omicron BA.4-5 variants to elicit adaptive immune responses against multiple circulating viral lineages.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:30:35.962Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention in adults and adolescents (booster dose)"}]},"trialDetails":[{"nctId":"NCT05951920","phase":"NA","title":"Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-05","conditions":"COVID-19","enrollment":12},{"nctId":"NCT05556720","phase":"PHASE3","title":"Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Monash University","startDate":"2022-12-01","conditions":"HIV, Organ Transplantation, Lymphoma, Non-Hodgkin","enrollment":960},{"nctId":"NCT05075538","phase":"PHASE4","title":"COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2","status":"TERMINATED","sponsor":"Jules Bordet Institute","startDate":"2021-12-01","conditions":"Cancer","enrollment":152},{"nctId":"NCT05930730","phase":"PHASE2","title":"Immunogenicity and Safety of Comvigen (Bivalent) Vaccine","status":"UNKNOWN","sponsor":"Chulalongkorn University","startDate":"2023-10-09","conditions":"Safety of a Single Dose of COMVIGEN Vaccine, Reactogenicity of a Single Dose of COMVIGEN Vaccine, Immunogenicity of a Single Dose of COMVIGEN Vaccine","enrollment":450},{"nctId":"NCT04977479","phase":"PHASE2","title":"The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-08","conditions":"Systemic Allergic Reaction","enrollment":20},{"nctId":"NCT05749926","phase":"PHASE3","title":"Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-05-16","conditions":"Vaccine Reaction, COVID-19","enrollment":248}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Comirnaty Original/Omicron BA.4-5","genericName":"Comirnaty Original/Omicron BA.4-5","companyName":"Jules Bordet Institute","companyId":"jules-bordet-institute","modality":"Biologic","firstApprovalDate":"","aiSummary":"This bivalent mRNA vaccine encodes spike proteins from the original SARS-CoV-2 strain and the Omicron BA.4-5 variants to elicit adaptive immune responses against multiple circulating viral lineages. Used for COVID-19 prevention in adults and adolescents (booster dose).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}